Blockchain
Isomorphic Labs Raises $5 Billion for AI Drug Design
Publication: The Defiant
Author: The Defiant
Source published: 17/11/2026, 12:11:21 UTC
Briefing created: 17/11/2026, 12:14:06 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 17/11/2026, 12:12:25 UTC.
Briefings
Isomorphic Labs secured a Series C funding round from Alphabet, raising $5 billion to advance its AI-driven drug discovery programs. The company plans to initiate clinical trials for its first therapeutic products shortly after this investment. The funding was led by Greenoaks and Sequoia, with Alphabet's investment occurring in the same round.
Key points
- Isomorphic Labs raised $5 billion in a Series C funding round led by Greenoaks and Sequoia.
- Alphabet invested in the same round to support Isomorphic's first therapeutic programs for clinical trials.
Context
Isomorphic Labs is an AI-focused company developing drug discovery solutions. The funding round is a key milestone for its transition from R&D to clinical trial phases.
Limitations
The evidence is a single article snippet from November 2026. Specific dates for clinical trial start, exact number of clinical sites, and specific drug names are not provided in the source.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 17/11/2026, 12:14:06 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeigtbvz23remertwaw62wkue2kd5sxqbytpdam7x2snjes7ypli7my